FDA Approves Gilead’s Bixlenvo for HIV Treatment
Foster City, California, August 27, 2026 Gilead Sciences, Inc. announced that the U.S. Food and Drug Administration (FDA) has...
HIV Treatment
Advertisement
ViiV Healthcare’s Tivicay PD Wins FDA Approval for Kids
LONDON, Aug 26, 2026 The U.S. Food and Drug Administration (FDA) has approved Tivicay PD (dolutegravir) from ViiV Healthcare...
ViiV Healthcare Reports Positive Phase IIIb Dovato Results
London, July 27, 2026 ViiV Healthcare has announced positive Week 48 results from the Phase IIIb VOGUE study, demonstrating...
Gilead Sciences and Merck & Co. Deliver Positive ISLEND Phase 3 Results
FOSTER CITY, Calif. & RAHWAY, N.J., July 22, 2026 Gilead Sciences and Merck announced detailed results from the Phase...
Gilead Sciences Presents New HIV Prevention and Treatment Data at AIDS 2026
FOSTER CITY, Calif., July 22, 2026 Gilead Sciences announced an extensive scientific program for the 26th International AIDS Conference...
Advertisements
Pharmascience Launches pms-DOLUTEGRAVIR in Canada
MONTREAL, April 29, 2026 Pharmascience Canada has announced the official launch of ᴾʳpms-DOLUTEGRAVIR (dolutegravir tablets), marking an important milestone...
Merck FDA Approval of IDVYNSO HIV Treatment Drug
Rahway, New Jersey, USA – April 21, 2026 In a major breakthrough for HIV therapeutics, Merck has received U.S....
Gilead Advances HIV Innovation with Breakthrough EACS 2025 Data
Barcelona, Spain – October 15, 2025 – Gilead Sciences, Inc. (NASDAQ: GILD) unveiled new data across its HIV prevention...
Advertisement
